Page 29 - குறைந்தபட்சம் ஆக்கிரமிப்பு அறுவை சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Yann Le Cam, Gregory Moore, and Wolfram Nothaft, Author at MedCity News

Yann Le Cam, Gregory Moore, and Wolfram Nothaft, Author at MedCity News
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

Gregory mooreWolfram nothaftMicrosoft healthYann le camChief executive officerRare diseases europeCorporate vice presidentChief medical officerGlobal commissionDiagnostic odysseyRare diseaseWeight lossMedical devicesHealthcare innovationMedcity newsMedcity news

Mayo Clinic strikes remote patient monitoring partnership with NXgenPort

Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.

United statesTufia haddadCathy skinnerDigital healthYork mount sinai health systemLucem healthCurrent healthMayo clinicWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock health

Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups

Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors has $515 million for its second fund investing in biotech startups. Portfolio Manager Chris Garabedian says Perceptive Xontogeny Ventures Fund II is looking to make Series A investments in early-stage companies with assets that can show a path to clinical testing. Shares0 When Chris Garabedian set out early last year to raise money for a second Perceptive Advisors fund focused on early-stage biotech startups, it took just a matter of months to draw interest from investors willing to commit more than $1 billion total. The fund could have closed with that much money, maybe more, said Garabedian, the portfolio manager. But it ended up with a little more than half of that, which he described as “the right size.”

University of pennsylvaniaUnited statesBen askewLandos biopharmaQuellis biosciencesChris garabedianFred calloriCatabasis pharmaceuticalsGilead sciencesNational institute of healthRosalind franklin universityDuke universityPerceptive advisorsPerceptive xontogeny venturesSarepta therapeuticsNephraegis therapeutics

How a national nursing license could improve patient care during a crisis

MedCity News How a national nursing license could improve patient care during a crisis While the Covid-19 pandemic is diminished with the introduction of vaccines, the need for a national license model is still prevalent as we face other serious health challenges like natural disasters and social conflict. Shares0 The nursing shortage has been prevalent for many decades and only continues to escalate. In fact, the World Health Organization estimates that by 2035 there will be a 12.9 million healthcare worker deficit largely comprised of nurses. During crisis moments like we experienced when Covid-19 hit in March 2020, there are various hurdles that obstruct the ability of appropriately skilled and licensed healthcare professionals to respond to the care that is required, such as being trapped at home in a natural disaster or falling ill to disease as we witnessed in the Covid-19 pandemic. Furthermore, there could be a shortage of nurses with the required specialty skill set.

United statesAmerican organization for nursing leadershipHospital corporation of america healthcareNational association of travel healthcare organizationsWorld health organizationUs department of commerceNational associationTravel healthcare organizationsNurse licensure compactAmerican organizationNursing leadershipHospital corporationAmerica healthcareWeight lossMedical devicesHealthcare innovation

Bigfoot Biomedical gets FDA clearance for smart insulin pen caps

MedCity News Bigfoot Biomedical gets FDA clearance for ‘smart’ insulin pen caps The startup received 510(k) clearance for its “smart” insulin pen cap, which pulls in data from users’ connected glucose monitor to help them calculate the right dose. Shares0 Bigfoot Biomedical received FDA clearance for its smart pen system. Photo credit: Bigfoot Biomedical In a significant step forward, Bigfoot Biomedical got the greenlight from the Food and Drug Administration for its “smart” insulin pen cap, developed to be paired with a continuous glucose monitor. It received 510(k) clearance for use among individuals ages 12 and up with Type 1 or Type 2 diabetes who use multiple-dose injection therapy.

Jeffrey brewerEli lillyBryan mazlishDrug administrationNovo nordiskBigfoot biomedicalExecutive board director bryan mazlishMedcity newsAbbott laboratorie freestyle libreWeight lossMedical devicesHealthcare innovationMedcity newsSan franciscoLife sciencesRock health